1. The percentage of patients with baseline BSA ≥ 3% in the ITT population who achieved (a) PASI 75, (c) PASI 90, and (e) PASI 100 during the 24-week double-blind period (weeks 0–24) and in the EPP during the extension period (weeks 28–52).
The percentage of patients with baseline BSA ≥ 3% in the ITT population who achieved (a) PASI 75, (c) PASI 90, and (e) PASI 100 during the 24-week double-blind period (weeks 0–24) and in the EPP during the extension period (weeks 28–52). The percentage of patients assigned to ixekizumab from the ITT population from Week 0 up to Week 52 who achieved (b) PASI 75, (d) PASI 90, and (f) PASI 100. Missing data imputed by NRI. ADA: adalimumab; BSA: body surface area; EPP: extension period population; ITT: intent to treat; IXEQ4W: ixekizumab every 4 weeks; IXEQ2W: ixekizumab every 2 weeks; NRI: non-responder imputation; PASI: Psoriasis Area and Severity Index; PBO: placebo.
Désirée van der Heijde et al. J Rheumatol 2018;45:
©2018 by The Journal of Rheumatology